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Abstract 1 
 Several phase I/II studies of chemoradiotherapy for gastric cancer have 2 
reported promising results, but the significance of preoperative radiotherapy in addition 3 
to chemotherapy has not been proven. In this study, a systematic literature search was 4 
performed to capture survival and postoperative morbidity and mortality data in 5 
randomised clinical studies comparing preoperative (chemo)radiotherapy or 6 
chemotherapy versus surgery alone, or preoperative chemoradiotherapy versus 7 
chemotherapy for gastric and/or gastro-oesophageal junction (GOJ) cancer. Hazard 8 
ratios (HRs) for overall mortality were extracted from the original studies, individual 9 
patient data provided from the principal investigators of eligible studies or the earlier 10 
published meta-analysis. The incidences of postoperative morbidities and mortalities 11 
were also analysed. In total 18 studies were eligible and data were available from 14 of 12 
these. The meta-analysis on overall survival yielded HRs of 0.75 (95% CI 0.65–0.86, 13 
P<0.001) for preoperative (chemo)radiotherapy and 0.83 (95% CI 0.67-1.01, P=0.065) 14 
for preoperative chemotherapy when compared to surgery alone. Direct comparison 15 
between preoperative chemoradiotherapy and chemotherapy resulted in a HR of 0.71 16 
(95% CI 0.45–1.12, P=0.146). Combination of direct and adjusted indirect comparisons 17 
yielded a HR of 0.86 (95% CI 0.69-1.07, P=0.171). No statistically significant 18 
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differences were seen in the risk for postoperative morbidity or mortality between 1 
preoperative treatments and surgery alone, or preoperative (chemo)radiotherapy and 2 
chemotherapy. Preoperative (chemo)radiotherapy for gastric and GOJ cancer showed 3 
significant survival benefit over surgery alone. In comparisons between preoperative 4 
chemotherapy and (chemo)radiotherapy, there is a trend towards improved survival 5 
when adding radiotherapy, without increased postoperative morbidity or mortality. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
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Introduction 1 
 In Western countries, about two thirds of patients with gastric cancer have 2 
locally advanced disease at diagnosis and inevitably the R0 resection rate and prognosis 3 
after surgery alone are miserable in this clinical setting.1 4 
 In many new cases of gastric cancer, adequate locoregional and systemic 5 
disease control is difficult to obtain with resection alone, therefore surgery is frequently 6 
combined with preoperative cytoreductive treatment in contemporary clinical practice. 7 
A previous meta-analysis comparing the long-term survival between preoperative 8 
chemotherapy with or without radiotherapy and surgery alone in patients with 9 
adenocarcinoma of the stomach, gastro-oesophageal junction (GOJ) or lower 10 
oesophagus suggested a survival benefit of preoperative chemotherapy.2 In this context, 11 
it should be noted that a corresponding survival benefit of preoperative radiotherapy 12 
alone has been alleged in a previous meta-analysis.3  13 
 Several phase I/II studies have presented promising results from the 14 
combination of preoperative chemotherapy and radiotherapy in patients with potentially 15 
resectable gastric cancer.4-6 Given the established validity of chemoradiotherapy for 16 
gastric cancer, the significance of preoperative radiotherapy as an adjunct to 17 
chemotherapy in patients with potentially resectable gastric cancer warrants better 18 
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scientific validation. To date, however, the sole direct randomised comparison between 1 
preoperative chemoradiotherapy versus chemotherapy alone focused on patients with 2 
GOJ cancer has been reported by Stahl et al.7 This study showed a significantly higher 3 
pathologic complete response rate and a tendency toward an improved 3-year survival 4 
rate by the addition of radiotherapy. 5 
 Evidence from comparative head to head (direct) trials is often limited or 6 
unavailable, why indirect comparisons are mandated.8 This is particularly the case with 7 
chemoradio- and chemotherapy when used preoperatively. A simple but inappropriate 8 
statistical method for indirect comparison is to compare the results of individual arms 9 
from different trials as if they were from the same randomised trial. This naive type of 10 
indirect comparison has been criticized for discarding the within trial comparison, and 11 
thereby increasing the liability to bias. In contrast, the adjusted indirect comparison can 12 
take advantage of the strength of randomised clinical trials in making unbiased 13 
comparisons. In the present study, the indirect comparison of different interventions is 14 
adjusted by comparing the results of their direct comparisons with a common control 15 
group.8 16 
 17 
 The objectives of the current study were threefold: firstly, to perform a careful 18 
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literature survey to assess the feasibility of performing a meta-analysis concerning 1 
outcome after preoperative treatment added to surgery compared to surgery alone in 2 
patients with gastric cancer including GOJ adenocarcinoma. Secondly, we wanted to 3 
analyze the compiled database with regard to the main outcomes of interest: 4 
postoperative morbidity, perioperative mortality and long-term survival for preoperative 5 
chemotherapy and chemoradiotherapy, separately. Finally, we aimed to clarify the 6 
differences in endpoints mentioned above between preoperative chemotherapy and 7 
chemoradiotherapy by direct and adjusted indirect comparison analyses. 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Patients and methods 1 
Eligibility criteria  2 
 Eligible studies were randomised clinical trials in which patients fulfilled the 3 
following criteria: adenocarcinoma of the stomach and/or GOJ; no previous treatment; 4 
tumours clinically diagnosed as resectable. Trials comparing preoperative chemotherapy 5 
plus surgery with surgery alone, preoperative radiotherapy with or without 6 
chemotherapy [(chemo)radiotherapy] plus surgery with surgery alone, and preoperative 7 
chemoradiotherapy plus surgery with chemotherapy plus surgery were included. To be 8 
regarded as preoperative, chemotherapy had to be administered before surgery, but trials 9 
on perioperative therapy were also included. Articles for which the full text was not 10 
available in English were excluded. 11 
 12 
Outcome measures 13 
 The primary outcome was overall survival defined as time from the date of 14 
randomisation until death. Secondary outcomes were progression free survival, defined 15 
as time from randomisation until tumour progression or death, postoperative morbidity 16 
and perioperative mortality. 17 
 18 
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Information sources, search, and study selection  1 
 Eligible trials were identified from earlier published meta-analyses and 2 
systematic electronic search. MEDLINE, Central (Cochrane clinical trials database) and 3 
EMBASE database were explored for studies published up to July, 2013 using the 4 
following terms and search formula: (stomach OR esophagus) AND cancer AND 5 
preoperative. The searches were limited to articles on randomised clinical trials and 6 
published in English. Furthermore, potentially relevant articles were identified by 7 
manually searching reference lists of all articles retrieved. Jadad’s score was used to 8 
assess the risk of bias of individual studies.9 9 
 10 
Individual patient data 11 
 For eligible studies, individual patient data (IPD) were solicited from the 12 
principal investigators of each study. Survival data were requested for the 13 
intention-to-treat population recruited from each trial. The investigators were asked to 14 
provide the most complete and updated follow-up data, even if the follow-up was longer 15 
than that used in the respective publication. Data not available upon database closure, 16 
either because IPD had not been provided or because full manuscripts had not been 17 
published, were not included in the final meta-analysis.  18 
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 1 
Data collection processes and clinical endpoint 2 
 Data were extracted by the first author (KK). Any discrepancies were dealt 3 
with by discussion among the authors and a consensus was reached. The following 4 
general information was extracted from each study: first author, year of publication, the 5 
number of patients who were randomised, and those who received surgery. Hazard 6 
ratios (HRs) for overall mortality were extracted as the summary statistic directly from 7 
the original studies or provided IPD. If they were not available, HRs were estimated 8 
indirectly by either using the number of randomised patients, the number of events 9 
occurred during observation period and P values for the log-rank test or, if no other 10 
information was available, by reading off survival curves as suggested by Parmar et al.10 11 
The 95% confidence interval (CI) for each HR was extracted directly from the original 12 
report or from IPD if available. Otherwise these variables were estimated indirectly by 13 
using the information available; e.g. data from earlier published meta-analyses. Risk 14 
ratios (RRs) for postoperative morbidity and mortality were also extracted directly from 15 
the original studies or provided IPD. In the analyses of morbidity rate, the incidences of 16 
the following postoperative complications were extracted: any complication, cardiac 17 
complication, respiratory complication, anastomotic leakage, and pancreatitis/pancreatic 18 
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fistula. Respiratory complications included pneumonia, acute respiratory distress 1 
syndrome (ARDS), pulmonary embolism, and respiratory failure. Diagnosis of 2 
postoperative pancreatic fistula was based on the International Study Group of 3 
Pancreatic Fistula (ISGPF) definition.11 However, cases where the pancreatic fistula was 4 
diagnosed solely on clinical grounds by the primary investigators were also included. 5 
The following mortality related information was extracted: 30-day postoperative 6 
mortality and total postoperative mortality and treatment-related mortality. Total 7 
postoperative mortality was defined as any in-hospital death or any post-discharge death 8 
that could be related to a postoperative complication. Treatment-related mortality was 9 
defined as the sum of total postoperative mortality and death before surgery caused by 10 
adverse side effects of neoadjuvant treatment. 11 
 12 
Statistical analysis 13 
 The meta-analysis was performed according to the recommendations specified 14 
in the PRISMA guidelines using STATA ver. 11.2 (StataCorp, Texas, USA).12 Statistical 15 
analysis was carried out using the HR for survival analyses and the RR for 16 
postoperative morbidity and mortality as the summary statistics. Random-effects models 17 
were used to estimate the summary statistics and confidence intervals because 18 
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preoperative treatment regimens and surgical procedures used in the trials were 1 
heterogenic and thus heterogeneity of the effect across different regimens could not be 2 
excluded a priori. Locational subgroup analysis was performed and no other subgroups 3 
were examined. Higgins’ I squared was the statistic used to test for heterogeneity, and 4 
the inverse of variance method was selected to combine results and calculate the 5 
heterogeneity among subgroups. The pooled HRs and RRs were reported with 95 per 6 
cent confidence intervals (CIs). In the analysis comparing preoperative therapy plus 7 
surgery with surgery alone, the HRs represented the relative risk of overall mortality 8 
and RRs represented the relative risk of postoperative morbidities and mortalities when 9 
preoperative chemoradiotherapy or chemotherapy was followed by surgery compared 10 
with surgery alone. A summary statistic (HR or RR) greater than 1 indicated a higher 11 
overall mortality or postoperative morbidity/mortality rate in patients who received 12 
preoperative treatments and the point estimate of the HR or RR was considered 13 
statistically significant at a 95% confidence level if the 95% CI did not include 1.  14 
 In the direct comparison analysis between preoperative chemoradiotherapy plus 15 
surgery and preoperative chemotherapy plus surgery, HRs represented the relative risk 16 
of overall mortality and RRs represented the relative risk of postoperative morbidities 17 
and mortalities for a patient who received preoperative chemoradiotherapy followed by 18 
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surgery compared with a patient who received preoperative chemotherapy followed by 1 
surgery. A summary statistic (HR or RR) greater than 1 indicated a higher overall 2 
mortality or postoperative morbidity/mortality rate in patients who received 3 
preoperative chemoradiotherapy and the point estimate of the HR or RR was considered 4 
significant at a 95% confidence level if the 95% CI did not include 1. An adjusted 5 
indirect comparison method was applied for indirect comparison of preoperative 6 
chemoradiotherapy plus surgery and preoperative chemotherapy plus surgery using a 7 
common control group (surgery alone). The results from adjusted indirect comparisons 8 
were combined with the results from direct comparison of preoperative 9 
chemoradiotherapy plus surgery versus preoperative chemotherapy plus surgery. A 10 
weighted combination (c) of the results from adjusted indirect comparison (i) and the 11 
direct comparison (d) was computed as an inverse variance weighted average. The 12 
weighted average and variance (Var) of the combination were calculated as: 13 
 Weighti=1 / Var(lnHRi), Weightd=1 / Var(lnHRd) 14 
 lnHRc=(Weighti * lnHRi + Weightd * lnHRd) / (Weighti + Weightd) 15 
 Var(lnHRc)=1 / (Weighti + Weightd) 16 
 To examine the consistency between the adjusted indirect comparison and the 17 
direct comparison, the discrepancy between the adjusted indirect comparison and the 18 
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direct comparison was evaluated by dividing the difference in the lnHR (lnHRi - lnHRd) 1 
by the standard error of the difference (Ҁ[Var(lnHRi) + Var(lnHRd)]), and comparing 2 
the resulting number with a standard normal distribution to obtain a P-value.13 3 
 Funnel plots were used to assess publication bias, where asymmetry implied 4 
that results were subject to reporting or publication bias. Begg’s test was also used to 5 
assess the bias, where an absolute z value over 1.96 implied that results were 6 
significantly subject to bias.14 7 
  8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Results 1 
Study selection 2 
 In total 18 studies7,15-31 were eligible (Fig 1). Eight were randomised 3 
comparisons of preoperative (chemo)radiotherapy versus surgery alone21-27,30, 8 were 4 
randomised comparisons of preoperative chemotherapy versus surgery alone 5 
15,17-20,28,29,31, and 2 were randomised comparisons of preoperative chemoradiotherapy 6 
versus preoperative chemotherapy.7,16 One study was a 3-arm study that compared 7 
preoperative chemotherapy using oral 5’-DFUR versus preoperative chemotherapy 8 
using intravenous 5-FU plus cisplatin versus surgery alone.31 This study was treated as a 9 
2-arm study that compared preoperative chemotherapy versus surgery alone and the 10 
patients in two groups of preoperative chemotherapy were combined. In three studies, 11 
patients in the preoperative chemotherapy group received postoperative chemotherapy if 12 
they were fit.17,19,29 One study included intraoperative radiotherapy in addition to 13 
preoperative radiotherapy.23 14 
  15 
Individual patient data (IPD) 16 
 Requests for IPD were sent to the corresponding authors of primary 17 
investigators of all 18 eligible studies by either air mail or email on October 3, 2013 and 18 
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data analyses were started on February 6, 2014. Seven authors gave replies by the time 1 
analyses started. 7,16-18,20,24,26 IPD were provided by two authors16,20 and complementary 2 
data were provided by one author.7 The numbers of patients contained in IPD data sets 3 
were identical with the intention-to-treat population reported in the publications. Any 4 
extreme and implausible outliers were not identified in the provided IPD.  5 
 6 
Risk of bias within studies 7 
 All studies were randomised clinical trials. The randomisation method used 8 
was specified in 14 out of 18 trials.7,15-19,21-26,29,30 Seven studies applied stratification for 9 
some factors.7,17-19,24,25,29 The minimisation method was used in three15,17,29 and the 10 
block randomisation was used in three.16,18,26 Blinding patients and clinicians to 11 
interventions was not evaluated because it was not possible given the design of the trials. 12 
No dropouts were observed in 3 trials21,28,30 and detailed information of dropouts was 13 
available in 14 trials.7,15-20,22-27,29 Average Jadad’s score, based on only three evaluation 14 
items (randomisation, description and adequacy of randomisation method, and 15 
dropouts), was 2.5. 16 
 17 
Surgical procedures 18 
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 The details of the surgical procedures were mentioned in 11 trials. 1 
7,16,17,19-23,27,29,31 Gastrectomy was the most common surgical procedure in 6 trials. 2 
17,20-23,31 In the other 5 trials oesophagectomy was the most common procedure in their 3 
original report.7,16,19,27,29 The extent of lymphadenectomy was described in 8 trials. 4 
7,16-18,20,22,23,29 D2 and D1 lymphadenectomy was mostly performed in 47,17,20,29 and in 3 5 
18,22,23 trials, respectively. Oesophagectomy with the dissection of the lymph nodes in 6 
the lower mediastinum, at the origin of the left gastric artery and the splenic artery to 7 
the hilum of the spleen was performed in one trial.16 Survival data or postoperative 8 
morbidity and mortality for each surgical procedure or lymphadenectomy were not 9 
separately reported in any of the trials. 10 
 11 
Overall survival 12 
 Overall survival was reported in all 18 trials, while 4 trials among them were 13 
excluded from the meta-analysis because they included oesophageal cancer patients 14 
without any possibility to extract tumour site specific results from the original reports 15 
and IPDs were not provided.15,24-26 Therefore the meta-analysis was performed with 14 16 
trials 7,16-23,27-31 (Fig.1, Table 1). This was also true of the following meta-analysis on 17 
progression free survival, morbidity, and mortality. In 5 trials data were obtained from 18 
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earlier published meta-analyses by Ronellenfitsch, which was performed by combining 1 
IPD and aggregate data.2,17,19,27,29,31 The current meta-analysis yielded a pooled HR of 2 
0.75 (95% CI 0.65–0.86, P<0.001) for preoperative (chemo)radiotherapy compared to 3 
surgery alone (Fig. 2a) and a HR of 0.83 (95% CI 0.67-1.01, P=0.065) for preoperative 4 
chemotherapy compared to surgery alone (Fig. 2b). Direct comparison of preoperative 5 
chemoradiotherapy versus preoperative chemotherapy was performed including 2 trials, 6 
which showed a pooled HR of 0.71 (95% CI 0.45–1.12, P=0.146) for preoperative 7 
chemoradiotherapy compared to preoperative chemotherapy (Fig. 2c).  Overall, 8 
adjusted indirect comparison yielded a HR of 0.91 (95% CI 0.71-1.16, P=0.445) for 9 
preoperative (chemo)radiotherapy compared to preoperative chemotherapy (Table 2). 10 
Combination of direct comparisons and adjusted indirect comparisons of all patients 11 
yielded a HR of 0.86 (95% CI 0.69-1.07, P=0.171) for preoperative 12 
(chemo)radiotherapy compared to preoperative chemotherapy (Table 2).  13 
 Tumour site specific subgroup analysis was possible only in GOJ cancer, which 14 
showed a HR of 0.74 (95% CI 0.50-1.09, P=0.131) for preoperative 15 
(chemo)radiotherapy compared to preoperative chemotherapy (Table 2). 16 
 17 
Progression free survival 18 
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 Progression free survival was available for GOJ cancer in 2 trials which 1 
compared preoperative chemoradiotherapy to preoperative chemotherapy (7;16. Direct 2 
comparison meta-analysis yielded a HR of 0.70 (95% CI 0.45-1.07. P=0.101) for 3 
preoperative chemoradiotherapy compared to preoperative chemotherapy (data not 4 
shown). 5 
 6 
Morbidity and mortality 7 
 There was considerable variation in morbidity between the single studies with 8 
rates in the single arms ranging from 2.9% (Zhao31, preoperative chemotherapy group) 9 
to 98.0% (Stahl7, preoperative chemoradiotherapy group). We were unable to 10 
demonstrate that (chemo)radiotherapy or chemotherapy given preoperatively increased 11 
the risk of any type of postoperative complication, cardiac complication, respiratory 12 
complication, anastomotic leak, pancreatitis/pancreatic fistula, 30-day mortality or total 13 
postoperative mortality as compared to surgery alone (Table 3). Adjusted indirect 14 
comparison showed no significant risk enhancement for any morbidity or mortality 15 
when preoperative (chemo)radiotherapy and chemotherapies were given (Table 3). 16 
Direct comparison between preoperative chemoradiotherapy and chemotherapy again 17 
revealed the same risk for morbidity as well as mortality (Table 3). Combination of 18 
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direct comparisons and adjusted indirect comparisons gave basically the same outcome 1 
(Table 3). Only one preoperative death was reported; a patient in chemotherapy group 2 
died preoperatively presumably due to chemotherapy induced toxicity in the direct 3 
comparison between preoperative chemoradiotherapy and chemotherapy.7 Therefore, it 4 
seemed not to be significant to evaluate treatment-related mortality besides total 5 
postoperative mortality. Furthermore, tumour site specific subgroup analysis was not 6 
feasible regarding morbidity or mortality. Any discrepancies in the findings of the 7 
adjusted indirect comparisons and the direct comparisons were assessed and no such 8 
impact was revealed on any type of morbidity or mortality. 9 
 10 
Risk of bias across studies 11 
 There was no noticeable asymmetry in the funnel plots and absolute z values in 12 
Begg’s test were less than 1.96 in all analyses (data not shown). Therefore, no 13 
publication bias seemed to be present. 14 
 Differences in interventions might also introduce bias. Four out of 5 trials 15 
comparing preoperative (chemo)radiotherapy to surgery alone used only radiotherapy as 16 
a preoperative therapy in the treatment arm, while another trial used cisplatinum- 17 
fluorouracil based chemotherapy which is the most common regimen in the trials 18 
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comparing preoperative chemotherapy to surgery alone or preoperative 1 
chemoradiotherapy to chemotherapy. The total amount of cisplatin and fluorouracil 2 
varied from 150 mg/m2 to 600 mg/m2 and 500 mg/body to 30000 mg/m2, respectively. 3 
Cunningham et al. used epirubicin in combination with cisplatin and fluorouracil.17 4 
Hartgrink et al. used methotrexate and doxorubicin instead of cisplatin in combination 5 
with fluorouracil.18 The median total dose of radiation was 40 (range 20-40) Gy, and the 6 
median dose fraction was 2.7 (2–5 Gy. Skoropad et al. used 20 Gy of intraoperative 7 
radiotherapy in combination with 20 Gy of preoperative radiotherapy.23 Preoperative 8 
radiation therapy was given concurrently with chemotherapy in all 3 trials that used the 9 
combination.7,16,27 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Discussion 1 
 In total 18 studies were eligible when we scrutinized the relevant literature and 2 
among these data were available from 14 of them. The subsequent meta-analysis on 3 
overall survival yielded a HR of 0.75 for preoperative (chemo)radiotherapy compared to 4 
surgery alone in resectable gastric and GOJ cancer, suggesting an important therapeutic 5 
effect. We also found that preoperative chemotherapy in resectable gastric and GOJ 6 
cancer showed a strong trend towards better long-term survival compared to surgery 7 
alone, although not statistically significant. It should be noted that four out of five 8 
studies on (chemo)radiotherapy in the analysis were comparisons between preoperative 9 
radiotherapy without any chemotherapy and surgery alone.21-23,30 Our results basically 10 
accord those from a previously completed meta-analysis by Fiorica et al. suggesting that 11 
preoperative radiotherapy for resectable stomach cancer improves survival compared to 12 
surgery alone.3 These results suggest a quite promising potential of preoperative 13 
radiotherapy for resectable stomach cancer, although preoperative radiotherapy without 14 
any chemotherapy is currently not a reasonable option, given the established evidence 15 
for the efficacy of preoperative multidrug chemotherapy.2 Moreover, using an adjusted 16 
indirect method it was possible to compare preoperative (chemo)radiotherapy and 17 
preoperative chemotherapy more comprehensively regarding the same outcome 18 
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variables. Combination of direct comparisons and adjusted indirect comparisons of 1 
overall patients provided evidence to suggest that preoperative (chemo)radiotherapy 2 
does show a tendency towards improving long-term survival compared to preoperative 3 
chemotherapy for resectable stomach cancer. These combined results are reliable 4 
because no statistically significant differences were observed between the results from 5 
direct and adjusted indirect comparisons. While four out of five studies on preoperative 6 
(chemo)radiotherapy used radiotherapy only, three out of eight studies on preoperative 7 
chemotherapy included postoperative chemotherapy as well.17,29,32 Despite these 8 
disadvantages, preoperative (chemo)radiotherapy showed a trend towards better 9 
long-term survival compared to chemotherapy alone highlighting the need for dedicated 10 
clinical studies. 11 
 Neither the direct nor the adjusted indirect comparisons demonstrated data to 12 
suggest that preoperative (chemo)radiotherapy increased the risk of postoperative 13 
morbidity or perioperative mortality neither when compared to preoperative 14 
chemotherapy alone nor to surgery alone. These combined results are also reliable since 15 
no differences were observed between the results from direct and adjusted indirect 16 
comparisons. These results are consistent with our previously published meta-analysis 17 
comparing postoperative morbidity and perioperative mortality between neoadjuvant 18 
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chemoradiotherapy and chemotherapy for oesophageal cancer.33 Accordingly, there are 1 
no additional concerns that have to be incorporated into the delicate balance between 2 
the tumour target and micrometastases issue for the cytotoxic therapy and its capability 3 
for enhanced surgical risks. 4 
 Recently, three different designs of adjuvant therapies for localized gastric 5 
cancer have shown improvement in survival based on large-scale, randomised clinical 6 
trials originating in three different regions in the world. The SWOG 9008/INT 0116 trial 7 
investigating postoperative chemoradiation in the United States34, the MAGIC trial of 8 
perioperative three-agent chemotherapy in Europe17, and postoperative chemotherapy 9 
regimens in Japan (the ACTS-GC trial)35 and in three Asian countries (the CLASSIC 10 
trial)36 have launched a multimodality therapeutic concept in gastric and GOJ cancers. 11 
 There are some drawbacks confined to postoperative adjuvant therapy for 12 
stomach cancer connected with the high morbidity and mortality rate after gastrectomy 13 
with radical lymphadenectomy, often delaying and even precluding postoperative 14 
treatment. The Dutch trial comparing D1 and D2 lymphadenectomy, without adjuvant 15 
therapy, showed 10 % of postoperative mortality and 43 % of postoperative morbidity in 16 
the D2 group.37 This high morbidity and mortality may have discouraged from the use 17 
of postoperative adjuvant therapy, especially in the West. This makes comparisons 18 
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between preoperative and postoperative treatment difficult, as postoperative therapy can 1 
only be given to the selected group of patients fit enough to tolerate it after surgery and 2 
surgical complications. 3 
 Not unexpectedly, a variety of surgical procedures and pre-and perioperative 4 
treatment regimens were used in both chemotherapy and radiotherapy currently 5 
reviewed, which introduces a risk of bias and, at the same time, represents a limitation 6 
of this meta-analytical approach.  7 
 There are also some methodological drawbacks in the present meta-analysis. It 8 
was mandated to use AIC because of the lack of studies comparing preoperative 9 
chemotherapy and chemoradiotherapy for non-cardia stomach (corpus and antrum) 10 
cancer, which was the reason for the invalidity of a tumour site specific subgroup 11 
analysis. The result of the AIC may be subject to greater bias (especially selection bias) 12 
than head-to-head randomised comparisons because the AIC is based on the transitivity 13 
assumption. If there are differences in selection criteria or distribution of effect 14 
modifiers between trials for chemoradiotherapy and for chemotherapy the transitivity 15 
assumption is violated and the result of the adjusted indirect effect may be biased. In our 16 
study, a possible modifier may be the tumour site since the overall I2=43 % and P=0.081 17 
in the preoperative chemotherapy versus surgery alone comparison is suggestive of a 18 
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moderate heterogeneity between the subgroups. If treatment-by-tumour site interaction 1 
exists, we must be very cautious before drawing conclusions on the findings from the 2 
AIC because the distribution of tumour site varied between trials for chemoradiotherapy 3 
and for chemotherapy. Furthermore, the increase in precision due to the combination of 4 
indirect and direct comparisons is valuable only when bias is absent. This condition 5 
once again relies on the similarity of the participants and interventions in the different 6 
trials. Two randomised clinical trials addressing this issue are ongoing in Australia 7 
(ClinicalTrials.gov Identifier: NCT01924819) and in China (NCT01815853). The 8 
results from these pivotal studies are awaited. 9 
 The present meta-analysis is an aggregation of tabulated data and IPD, which 10 
might jeopardize the robustness of the meta-analysis. Despite our effort to get IPD from 11 
all eligible RCTs, IPD were provided from only 2 primary investigators and 12 
compensatory tabulated data was provided from one investigator. In 6 studies, estimates 13 
were calculated from the data reported in original studies. In 5 studies, data were 14 
extracted from the meta-analysis by Ronellenfitsch.2 However the results from all the 15 
reviewed trials seemed consistent with the results from the IPD.  16 
 In conclusion, preoperative (chemo)radiotherapy for resectable gastric and GOJ 17 
cancer is associated to a significant survival benefit over surgery alone. Preoperative 18 
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chemotherapy alone seemed to act in the same direction. In adjusted indirect and direct 1 
comparisons between preoperative chemotherapy and chemoradiotherapy, the latter 2 
showed a trend towards better long-term survival, which could not be fully substantiated 3 
statistically. Neither of these neoadjuvant therapies increased the risk for postoperative 4 
morbidity or perioperative mortality. Although the results were not conclusive because 5 
of some methodological drawbacks, they raise an issue regarding a possible role for 6 
preoperative radiotherapy in the curatively intended treatment for stomach and GOJ 7 
cancer. 8 
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Author Year published Preoperative radiotherapy and chemotherapy regimens 
Tumour site No. of pts 
included 
in the MA 
Information source 
O GOJ S 
Preoperative radio(chemo)therapy plus surgery vs. surgery alone 
Shchepotin 1994 20 Gy of RT in 4 fractions 0 0 198 198 5- and 3-year survival, date of trial started and published 
Zhang 1998 40 Gy of RT in 20 fractions 0 370 0 370 Number of randomised pts and overall mortality and p-value 
Skoropad 2000 20 Gy of RT in 5 fractions plus 20 Gy as an IORT 0 78 78 Number of eligible pts and overall mortality and p-value 
Urba 2001 45 Gy of RT in 30 fractions; Two cycles of CT: Cis 20 mg/m² days 1–5; FU 300 mg/m² days 1–21; vinblastine 1 mg/m² days 1–4 100 0 0 Excluded 
Skoropad 2002 20 Gy of RT in 5 fractions 0 102 102 10- and 5-year survival, date of trial started and published 
Walsh 2002 40 Gy of RT in 15 fractions; Two cycles of CT: Cis 75 mg/m² on day 7; FU 15 mg/kg on days 1–5 74 39 0 39 
lnHR, selnHR from MA by 
Ronellenfitsch 
Tepper 
(CALGB 9781) 2008 
50.4 Gy of RT in 28 fractions; Two cycles of CT: Cis 60 mg/m² day 1; FU 1000 
mg/m² days 3–5 56 0 0 Excluded 
van Hagen 
(CROSS) 2012 
41.4 Gy of RT in 23 fractions; 5 weeks concurrent CT: carboplatin area under 
curve=2 mg/ml/min and paclitaxel 50 mg/m² on day 1 weekly 366 0 0 Excluded 
Preoperative chemotherapy plus surgery vs. surgery alone 
Wang 2000 Orally FPLC over 12.5 days (5-FU 160 mg/day) 0 60 0 60 Number of randomised pts, death during 5 years and p-value 
Hartgrink 
(FAMTX) 2004 
Two to four cycles: methotrexate 1500 mg/m² on day 2; 5-FU 1500 mg/m² on day 
2; leucovorin 240 or 480 mg cumulative dose on days 3 to 4; doxorubicin 30 
mg/m² on day 15 
0 0 56 56 Number of eligible patients and overall mortality and p-value 
Cunningham 
(MAGIC) 2006 
Three cycles: epirubicin 50 mg/m² on day 1; Cis: 60 mg/m² on day 1; 5-FU 4200 
mg/m² cumulative dose on days 1 to 21) preop.; surgery 3 to 6 weeks after last 
chemotherapy dose; 3 cycles (see above) postop. starting 6 to 12 weeks after 
surgery 
73 58 372 430 lnHR, selnHR from MA by Ronellenfitsch 
Zhao 2006 Group 1: 800-1200 mg/day 5`-DFUR for 3-5 days,  Group 2: 500 mg 5-FU + 200mg/day CF for 3-5 days 0 0 54 54 
lnHR, selnHR from MA by 
Ronellenfitsch 
Kelsen 
(RTOG 8911) 2007 
Three cycles preoperatively: Cis 100 mg/m² day 1; FU 1000 mg/m² days 1–5; two 
cycles postoperatively: Cis 75 mg/m² day 1; FU 1000 mg/m² days 1–5 143 93 0 93 
lnHR, selnHR from MA by 
Ronellenfitsch 
Allum 
(OE02) 2009 Two cycles: Cis 80 mg/m² day 1; FU 1000 mg/m² days 1–4 720 82 0 0 Excluded 
Schuhmacher 
(EORTC 40954) 2010 
Two cycles: Cis 50 mg/m² day 1, 15 and 29; FU 2000 mg/m² and folinic acid 
500mg/m² days 1, 8, 15, 22, 29 and 36 0 144 144 IPD 
Ychou 
(ACCORD07) 2011 
Planned six perioperatively: (two or three cycles before surgery plus four or three 
cycles after surgery) of intravenous Cis (100 mg/m²) on day 1 and every 28 days 
continuous intravenous infusion of FU (800 mg/m² per day) for 5 consecutive 
days (days 1-5) 
25 144 55 199 lnHR, selnHR from MA by Ronellenfitsch 
Preoperative chemoradiotherapy vs. preoperative chemotherapy 
Stahl 
(POET) 2009 
30 Gy of RT in 15 fractions, commencing 2 weeks after last day of induction CT, 
(CT group) 15 weeks: Cis 50 mg/m² biweekly; FU 2000 mg/m²/day weekly; 
folinic acid 500 mg/m²/weekly (CRT group) 12 weeks (induction): Cis 50 mg/m² 
biweekly; FU 2000 mg/m²/day weekly; folinic acid 500 mg/m²/day weekly. 
Followed by Cis 50 mg/m² on day 1 and day 8 and etoposide 80 mg/m² on days 
3–5, concurrent with RT 
0 119 0 119 HR and CI for OS and PFS provided by the original trialist 
Burmeister 2011 
35 Gy of RT in 15 fractions commencing day 22, (CT group) Cis 80 mg/m² day 1 
and 21; FU 1000 mg/m²/day infusion over 96 h day 1 and 21 (CRT group) 1 cycle 
induction: Cis 80 mg/m² day 1 and FU 1000 mg/m²/day infusion over 96 h day 1. 
Followed by Cis 80 mg/m² day 1 and FU 800 mg/m²/day infusion over 96 h on 
day 1; concurrent with RT 
60 15 0 14* IPD 
*One patient with unknown histology tumour was excluded; O,oesophagus; GOJ, gastro-oesophageal junction (including cardia); S, stomach (corpus and antrum); No., number; pts, patients; MA, 
meta-analysis; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression free survival; IPD, individual patient data; RT, radiotherapy; IORT, intraoperative radiotherapy; CT, 
chemotherapy; NA, not available; Cis, cisplatin; FU, fluorouracil 
Table 1 Treatment regimens, sample size and information source for survival analyses in randomised trials eligible for the 
meta-analysis 
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Tumour site  HR 
95 % CI 
z P Lower Upper 
Overall 
Pre-op chemoradio vs. chemo (AIC) 0.91 0.71 1.16 -0.76 0.445 
Pre-op chemoradio vs. chemo 
(combination of DC and AIC) 0.86 0.69 1.07 -1.37 0.171 
Difference between DC and AIC    -0.91 0.363 
GOJ 
Pre-op chemoradio vs. chemo (AIC) 0.82 0.38 1.78 -0.51 0.613 
Pre-op chemoradio vs. chemo 
(combination of DC and AIC) 0.74 0.50 1.09 -1.51 0.131 
Difference between DC and AIC    -0.30 0.768 
Stomach 
Pre-op chemoradio vs. chemo (AIC) 0.77 0.53 1.10 -1.46 0.145 
Pre-op chemoradio vs. chemo 
(combination of DC and AIC) NA NA NA NA NA 
Difference between DC and AIC 㻌 㻌 㻌 NA㻌 NA㻌
HR, hazard ratio; CI, confidence interval; GOJ, gastro-oesophageal junction; CRTx, chemoradiotherapy; 
CTx, chemotherapy; DC, direct comparison; AIC, adjusted indirect comparison; NA, not available 
Table 2 Combination of direct and adjusted indirect comparisons of preoperative chemoradiotherapy with preoperative chemotherapy 
(overall survival) 
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Events 
 
Total 
  
RR 
95 % CI 
z P Lower Upper 
Any 
complication 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 44 91 0.97 0.64 1.48 0.15 0.881 
surgery alone 44 89 1     
Pre-op chemo vs. surgery 
alone 
chemo 20 102 1.87 0.96 3.65 1.83 0.067 
surgery alone 11 92 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 49 52 1.17 0.69 1.98 0.59 0.557 
chemo 46 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 44 91 0.52 0.24 1.14 -1.63 0.104 
chemo 20 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 93 143 0.91 0.59 1.41 -0.41 0.679 
chemo 66 163 1     
Difference between DC and 
AIC 
   
㻌 㻌 㻌 1.68 0.093 
Cardiac 
complication 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 2 91 2.93 0.31 27.60 0.94 0.348 
surgery alone 0 89 1     
Pre-op chemo vs. surgery 
alone 
chemo 2 102 0.36 0.07 1.96 1.18 0.238 
surgery alone 5 92 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 8 52 1.06 0.23 5.03 0.08 0.937 
chemo 9 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 2 91 8.10 0.49 134.82 1.46 0.145 
chemo 2 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 10 143 1.71 0.44 6.67 0.78 0.438 
chemo 11 163 1     
Difference between DC and 
AIC 
   
   -1.24 0.216 
Respiratory 
complication 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 23 91 1.52 0.86 2.68 1.43 0.153 
surgery alone 15 89 1     
Pre-op chemo vs. surgery 
alone 
chemo 8 102 2.82 0.78 10.20 1.58 0.113 
surgery alone 3 92 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 9 52 1.56 0.60 4.06 0.92 0.359 
chemo 8 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 23 91 0.54 0.13 2.19 -0.87 0.386 
chemo 8 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 32 143 1.12 0.51 2.46 0.27 0.785 
chemo 16 163 1     
Difference between DC and 
AIC 
   
   1.23 0.218 
 
 
 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 11 262 0.69 0.21 2.20 0.64 0.525 
surgery alone 16 288 1     
Pre-op chemo vs. surgery chemo 4 102 2.12 0.40 11.19 0.88 0.377 
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Anastomotic 
leak 
alone surgery alone 2 92 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 8 52 0.71 0.32 1.58 0.84 0.399 
chemo 12 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 11 262 0.32 0.04 2.47 -1.09 0.277 
chemo 4 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 19 314 0.64 0.30 1.34 -1.19 0.236 
chemo 16 163 1     
Difference between DC and 
AIC 
   
㻌 㻌 㻌 0.70 0.483 
Pancreatitis 
/Pancreatic 
fistula 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 18 91 0.56 0.05 5.88 0.48 0.629 
surgery alone 18 89 1     
Pre-op chemo vs. surgery 
alone 
chemo 3 102 7.41 0.39 140.77 1.13 0.183 
surgery alone 0 92      
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 0 52 
㻌 NA NA㻌 NA NA NA chemo 0 61 
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 18 91 0.08 0.00 3.28 -1.34 0.179 
chemo 3 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 18 143 NA NA NA NA NA chemo 3 163 
Difference between DC and 
AIC 
   
㻌 㻌 㻌 NA㻌 NA 
30-day 
mortality 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 1 171 0.23 0.03 1.97 1.34 0.181 
surgery alone 5 199 1     
Pre-op chemo vs. surgery 
alone 
chemo 3 102 7.41 0.39 140.77 1.33 0.183 
surgery alone 0 92 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 3 52 1.59 0.28 9.12 0.52 0.602 
chemo 2 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 1 171 0.03 0.00 1.20 -1.86 0.062 
chemo 3 102 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 4 223 0.76 0.16 3.69 -0.34 0.734 
chemo 5 163 1     
Difference between DC and 
AIC 
   
㻌 㻌 㻌 1.90 0.057 
 
 
 
 
 
Total 
postoperative 
mortality 
Pre-op chemoradio vs. 
surgery alone 
chemoradio 7 262 0.72 0.28 1.87 0.67 0.504 
surgery alone 11 288 1     
Pre-op chemo vs. surgery 
alone 
chemo 5 129 2.64 0.52 13.30 1.17 0.241 
surgery alone 2 121 1     
Pre-op chemoradio vs. 
chemo (DC) 
chemoradio 5 52 2.65 0.54 13.05 1.20 0.230 
chemo 2 61 1     
Pre-op chemoradio vs. 
chemo (AIC) 
chemoradio 7 262 0.27 0.02 2.94 -1.08 0.280 
chemo 5 129 1     
Pre-op chemoradio vs. 
chemo (combined) 
chemoradio 12 314 1.32 0.35 4.96 0.40 0.687 
chemo 7 190 1     
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Difference between DC and 
AIC 
   
㻌 㻌 㻌 1.56 0.118 
RR, risk ratio; confidence interval; DC, direct comparison; AIC, adjusted indirect comparison; NA, not available 
Table 3 Combination of direct and adjusted indirect comparisons of preoperative chemoradiotherapy with preoperative chemotherapy 
(morbidity and mortality) 
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Fig. 1 Flow diagram showing inclusion and exclusion of studies 
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a Preoperative chemoradiotherapy plus surgery vs. surgery alone 
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b Preoperative chemotherapy plus surgery vs. surgery alone 
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c Preoperative chemoradiotherapy plus surgery vs. preoperative chemotherapy plus surgery 
 
Fig. 2 Overall survival comparing a Preoperative chemoradiotherapy plus surgery to surgery alone, b 
Preoperative chemotherapy plus surgery to surgery alone and c Preoperative chemoradiotherapy plus 
surgery to preoperative chemotherapy plus surgery. GOJ, gastroesophageal junction; Haz. Ratio, hazard 
ratio; CI, confidence interval 
